<DOC>
	<DOCNO>NCT00422214</DOCNO>
	<brief_summary>The purpose study determine safety efficacy sustained-release quetiapine fumarate ( SeroquelÂ® ) treatment patient Acute Bipolar Depression 8 week . PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Phase III/Seroquel SR Bipolar Depression Monotherapy - US</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Affective Disorders , Psychotic</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent Documented diagnosis Bipolar 1 disorder Bipolar 11 disorder Outpatient status enrollment Patients &gt; 8 mood episode past 12 year Use prohibit medication Substance alcohol abuse dependence Current suicide risk suicide attempt within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar Depression ,</keyword>
	<keyword>Manic Depression</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Seroquel SR</keyword>
	<keyword>quetiapine fumarate</keyword>
</DOC>